casp3

Migration, Crosslink

📖

casp3

active

wiki page Created: 2026-04-02T07:19:32 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-casp3

📖 Wiki Page

gene2283 wordssynced 2026-04-02

casp3

Introduction

Pathway Diagram

...

casp3

Introduction

Pathway Diagram

Mermaid diagram (expand to render)

Caspase 3 (Casp3) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Caspase 3 (CASP3) is an executioner caspase that executes the final stages of [apoptosis](/mechanisms/apoptosis). It is encoded by the CASP3 gene located on chromosome 4q34 and is one of the most studied caspases in neurodegeneration research. As the principal executioner caspase, caspase-3 is responsible for the proteolytic dismantling of cellular components during programmed cell death. However, emerging research reveals that caspase-3 also has critical non-apoptotic functions in synaptic plasticity, learning, and memory. [@damelio2010][@gamblin2003]

<div class="infobox infobox-gene"> [@tatton2000]
<table>
<tr><th colspan="2" style="background:#f0f0f0;">Caspase 3</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>CASP3</td></tr>
<tr><td><strong>Full Name</strong></td><td>Caspase 3</td></tr>
<tr><td><strong>Chromosome</strong></td><td>4q34</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[837](https://www.ncbi.nlm.nih.gov/gene/837)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[600636](https://www.omim.org/entry/600636)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>[ENSG00000164305](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164305)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P42574](https://www.uniprot.org/uniprot/P42574)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">833 edges</a></td>
</tr>
</table>
</div>

Gene Information

<div class="infobox infobox-gene">
<table>
<tr><th>Symbol</th><td>CASP3</td></tr>
<tr><th>Full Name</th><td>Caspase 3</td></tr>
<tr><th>Chromosomal Location</th><td>4q34.1</td></tr>
<tr><th>NCBI Gene ID</th><td>[837](https://www.ncbi.nlm.nih.gov/gene/837)</td></tr>
<tr><th>OMIM</th><td>[600636](https://www.omim.org/entry/600636)</td></tr>
<tr><th>Ensembl</th><td>ENSG00000164305</td></tr>
<tr><th>UniProt</th><td>[P42574](https://www.uniprot.org/uniprot/P42574)</td></tr>
<tr><th>Gene Family</th><td>Caspase family, peptidase C14A subfamily</td></tr>
<tr><th>Protein Length</th><td>277 amino acids (active enzyme)</td></tr>
</table>
</div>

Protein Structure and Function

Domain Architecture

Caspase-3 is synthesized as an inactive zymogen (procaspase-3) consisting of: [@damelio2010]

Prodomain (N-terminal): Short prodomain (~30 amino acids) that lacks a CARD or DED domain, distinguishing caspase-3 from initiator caspases

Large Subunit (p20, ~20 kDa): Contains the catalytic cysteine residue (Cys163) and substrate-binding pocket

Small Subunit (p11, ~11 kDa): Completes the active site configuration

Linker Region: Contains the interdomain linker with cleavage sites (Asp9, Asp28, Asp175)

Activation Mechanism

Caspase-3 requires proteolytic cleavage for activation and is activated by both apoptotic pathways:

Intrinsic pathway: Mitochondrial MOMP → cytochrome c release → apoptosome formation → caspase-9 activation → caspase-3 cleavage

Extrinsic pathway: Death receptor activation → DISC formation → caspase-8 activation → caspase-3 cleavage

The cleavage process:

First cleavage: separates prodomain from the large subunit
Second cleavage: separates large and small subunits
Active enzyme: heterotetramer (p17/p11)₂

Substrate Specificity

Activated caspase-3 cleaves over 600 known substrates: [@snigdha2016]

DNA repair proteins: PARP, DNA-PKcs, XRCC1
Structural proteins: Lamin A/C, β-catenin, tubulin, actin
Signal transduction: PKC isoforms, Akt, BAD
Anti-apoptotic proteins: Bcl-2, Mcl-1, XIAP
Synaptic proteins: PSD-95, Synaptophysin, AMPA receptor subunits

Non-Apoptotic Functions

Caspase-3 has critical functions beyond cell death: [@sutton2019]

Synaptic Plasticity

Long-term depression (LTD): Local caspase-3 activation at synapses mediates AMPA receptor internalization
Synaptic pruning: Developmental and activity-dependent synapse elimination
Learning and memory: Caspase-3 is required for memory consolidation in certain paradigms

Cellular Processes

Cell cycle regulation: Caspase-3 can cleave cell cycle proteins
Differentiation: Role in neural progenitor cell differentiation
Migration: Affects neuronal migration during development

Important: Complete inhibition of caspase-3 may disrupt normal synaptic function, complicating therapeutic targeting.

Role in Neurodegeneration

Alzheimer's Disease

Caspase-3 plays multiple roles in AD pathogenesis: [@shimohama1999][@gamblin2003][@park2018]

Synaptic loss: Cleaves synaptic proteins including PSD-95, synaptophysin, leading to synaptic dysfunction and loss [@snigdha2016]

Tau cleavage: Generates truncated tau fragments that form aggregates more readily than full-length tau [@gamblin2003]

Cleavage at Asp421 generates Δtau421
Truncated tau spreads between neurons in a prion-like manner

3. Amyloid effects: Activated by Aβ toxicity through both intrinsic and extrinsic pathways

DNA damage: Cleaves PARP, leading to energy depletion and bioenergetic failure [@liu2018]

Apoptotic execution: Final executioner of the apoptotic cascade

Molecular Cascade in AD

Aβ oligomers bind to neuronal receptors
Calcium dysregulation and mitochondrial stress
Activation of initiator caspases (caspase-8, -9)
Caspase-3 activation and substrate cleavage
Synaptic dysfunction precedes neuronal loss

Parkinson's Disease

In PD, caspase-3 mediates dopaminergic neuron death: [@tatton2000][@mars操2020]

Mitochondrial dysfunction: Complex I inhibition leads to MOMP and caspase-3 activation

α-Synuclein toxicity: Oligomeric α-synuclein triggers caspase-3 activation

Oxidative stress: ROS accumulation damages mitochondria, triggering apoptosis

Neuroinflammation: Activated microglia release pro-inflammatory cytokines that sensitize neurons to apoptosis

Evidence: Active caspase-3 is elevated in PD substantia nigra

Dopaminergic Neuron Vulnerability

High metabolic demand with limited antioxidant capacity
Low Bcl-2 family anti-apoptotic proteins
Exposure to dopamine oxidation products
Age-related mitochondrial decline

ALS

Caspase-3 is elevated in ALS and contributes to motor neuron death: [@friedlander2017]

Motor neurons show caspase-3 activation
Contributes to neuromuscular junction denervation
Activated by excitotoxicity and mitochondrial dysfunction
Cleaves key structural proteins in motor neurons

Stroke and TBI

Following cerebral ischemia or trauma: [@walsh2021]

Executes necrotic and apoptotic cell death
Cleaves neuronal cytoskeletal proteins
Contributes to blood-brain barrier disruption
Caspase-3 inhibitors show neuroprotective effects in preclinical models

Huntington's Disease

Mutant huntingtin triggers mitochondrial dysfunction
Caspase-3 activation in striatal neurons
Contributes to medium spiny neuron loss

Therapeutic Targeting

Caspase-3 inhibitors have been extensively studied: [@walsh2021][@hyman2015]

| Agent | Mechanism | Status | Disease |
|-------|-----------|--------|---------|
| Z-DEVD-FMK | Irreversible inhibitor | Preclinical | Stroke, TBI |
| Ac-DEVD-CHO | Reversible inhibitor | Research | Neuroprotection |
| M826 | Caspase-3 selective | Research | AD |
| DEVD-peptide conjugates | Targeted delivery | Preclinical | Various |

Challenges

Non-apoptotic functions: Complete inhibition disrupts synaptic plasticity
BBB penetration: Most inhibitors don't cross the blood-brain barrier
Timing: Intervention likely needs to occur early in disease
Selectivity: Pan-caspase inhibitors have broader side effects

Alternative Approaches

Upstream targeting: Inhibit initiator caspases or upstream activators
Substrate protection: Develop peptides that prevent caspase-3 from cleaving critical substrates
Gene therapy: Dominant-negative caspase-3 constructs

Substrate-Specific Inhibition

Targeting specific caspase-3 substrates offers a promising strategy: [@gao2023]

Tau protection: Peptides that block caspase-3 cleavage of tau
Synaptic protein preservation: Inhibiting cleavage of PSD-95, synaptophysin
Nuclear substrate protection: Preventing PARP cleavage and DNA damage
Combination approaches: Multiple substrate protection strategies

Clinical Development Status

Caspase-3 inhibitors in the drug development pipeline: [@wang2024]

Preclinical candidates: Multiple selective inhibitors in development
Delivery methods: Focus on BBB-penetrant small molecules
Combination therapies: Dual caspase-3 and amyloid/tau targeting
Biomarker integration: Patient selection based on caspase-3 activity

Ferroptosis Cross-Talk

Caspase-3 has been implicated in ferroptosis, a form of regulated necrosis: [@xu2024]

Molecular intersection: Caspase-3 can influence ferroptosis pathways
GPX4 regulation: Cross-talk with key ferroptosis regulators
Therapeutic implications: Combined targeting approaches
Disease relevance: Implications for neurodegeneration

Structural Biology

Active Site Architecture

The caspase-3 active site provides targets for drug design: [@walsh2021]

Catalytic cysteine: Cys163 performs nucleophilic attack
Substrate binding pocket: Recognizes DEVD tetrapeptide sequence
Dimer interface: Active enzyme functions as a dimer
Allosteric regulation: Substrate binding induces conformational changes

Substrate Recognition

Caspase-3 cleaves over 600 known substrates with distinct specificities: [@gao2023]

Optimal sequence: Tetrapeptide recognition (DEVD)
Extended binding: Additional contacts beyond P4-P1
Substrate diversity: Proteins, lipids, and nucleic acids
Cleavage consequences: Activation, inactivation, or relocalization

Cellular and Molecular Mechanisms

Synaptic caspase-3 Activity

Local caspase-3 activation at synapses mediates critical functions: [@sutton2019][@galvan2020]

LTD induction: AMPA receptor internalization through caspase-3 cleavage
Synaptic pruning: Developmental and activity-dependent elimination
Memory consolidation: Required for certain memory paradigms
Spatial regulation: Local translation and activation at dendritic spines

Nuclear Events

Caspase-3 translocates to the nucleus during apoptosis: [@liu2018]

PARP cleavage: Generates death-inducing DNA fragments
Chromatin condensation: Nuclear lamina breakdown
Transcriptional effects: Alters gene expression programs
DNA repair inhibition: Impairs cellular repair capacity

Mitochondrial Cross-Talk

Caspase-3 interacts with mitochondrial proteins: [@chen2016]

Pro-apoptotic effects: Cleaves anti-apoptotic proteins
Cytochrome c release: Amplifies intrinsic pathway
Energy depletion: PARP cleavage causes NAD+ loss
Bioenergetic failure: ATP depletion terminates survival programs

Neuroinflammation Role

Caspase-3 in neuroinflammatory processes: [@liu2022]

Microglial activation: Regulates inflammatory responses
Cytokine processing: Can process inflammatory mediators
Immune cell death: Controls peripheral immune infiltration
Dual roles: Both pro-inflammatory and protective functions

Inflammatory Cascade Regulation

Caspase-3 contributes to neuroinflammation through multiple pathways: [@liu2022]

Cytokine activation: Processing of inflammatory interleukins
Microglial survival: Regulation of activated microglia
Blood-brain barrier: Effects on BBB integrity
Peripheral immune modulation: Cross-talk with systemic immunity

Imaging and Diagnostics

Caspase-3 Activity Imaging

Advanced imaging techniques for caspase-3: [@zhang2024]

Fluorescent probes: Activatable imaging agents
PET tracers: Radiolabeled caspase-3 inhibitors
Optical imaging: Intraoperative guidance
Longitudinal monitoring: Tracking disease progression

Diagnostic Applications

Clinical diagnostic potential:

Early detection: Identifying pre-symptomatic changes
Disease progression: Monitoring caspase-3 activity over time
Treatment response: Predicting therapeutic efficacy
Patient stratification: Selecting patients for caspase-targeted therapy

Therapeutic Delivery Strategies

Blood-Brain Barrier Penetration

Overcoming delivery challenges: [@walsh2021]

Lipid-based carriers: Improving brain penetration
Nanoparticle approaches: Targeted delivery systems
Intranasal delivery: Direct nose-to-brain pathways
Focused ultrasound: BBB opening for enhanced delivery

Cell-Type Specific Targeting

Selective targeting strategies:

Neuron-specific delivery: Leveraging neuronal receptors
Viral vectors: AAV-mediated gene therapy
Peptide conjugates: Cell-penetrating peptides
Antibody-based approaches: Engineered antibodies

Genetic Associations

Polymorphisms

rs12108497: May influence caspase-3 expression
rs3749919: Associated with AD risk in some populations

Expression Changes

CASP3 expression is elevated in AD brain, particularly in vulnerable regions
Active caspase-3 levels are elevated in PD substantia nigra
Increased in ALS motor neurons and spinal cord

Biomarker Potential

Caspase-3 cleavage products are being explored as biomarkers: [@kumar2015]

CSF biomarkers: Caspase-3 cleaved fragments detectable in cerebrospinal fluid
Blood biomarkers: Extracellular vesicles containing caspase-3 cleavage products
Therapeutic monitoring: Caspase-3 activity may predict treatment response

Interaction Network

Caspase-3 interacts with multiple proteins in the cell death machinery:

| Partner | Interaction Type | Function |
|---------|-----------------|----------|
| Caspase-8 | Upstream activator | Extrinsic pathway |
| Caspase-9 | Upstream activator | Intrinsic pathway |
| XIAP | Direct binding | Inhibitory regulation |
| PARP | Substrate | DNA repair cleavage |
| PSD-95 | Substrate | Synaptic protein cleavage |
| Synaptophysin | Substrate | Synaptic vesicle cleavage |
| Bcl-2 | Substrate | Anti-apoptotic cleavage |
| Lamin A/C | Substrate | Nuclear envelope cleavage |

Cross-Linking

[Caspase-8](/genes/casp8) - Extrinsic pathway initiator
[Caspase-9](/genes/casp9) - Intrinsic pathway initiator
[Caspase-6](/genes/casp6) - Related effector caspase
[PARP1](/genes/parp1) - DNA repair enzyme substrate

[Apoptosis](/mechanisms/apoptosis) - Programmed cell death pathway
[Synaptic Loss](/mechanisms/synaptic-loss-ad) - Early event in AD
[Tau Pathology](/mechanisms/tau-pathology) - NFT formation
[Neuroinflammation](/mechanisms/neuroinflammation) - Inflammatory processes

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[ALS](/diseases/als)
[Huntington's Disease](/diseases/huntingtons)

Disease Associations

| Disease | Role | Evidence |
|---------|------|----------|
| [Alzheimer's Disease](/diseases/alzheimers-disease) | Synaptic loss, tau cleavage | Elevated in AD brain[@shimohama1999] |
| [Parkinson's Disease](/diseases/parkinsons-disease) | Neuronal death | Active caspase-3 in SN[@tatton2000] |
| ALS | Motor neuron death | Activated in ALS models |
| Stroke | Ischemic injury | Mediates neuronal death |
| Huntington's Disease | Striatal neuron loss | Activated in HD models |

Expression in the Brain

CASP3 is ubiquitously expressed in the brain: [@damelio2010]

[Neurons](/entities/neurons): All neuronal subtypes, highest expression in pyramidal neurons
[Astrocytes](/entities/astrocytes): Lower expression than neurons
[Microglia](/entities/microglia): Activated microglia show increased expression
[Oligodendrocytes](/entities/oligodendrocytes): Variable expression

Region-Specific Patterns

Hippocampus: High expression in CA1-CA3 and dentate gyrus
Cortex: Layer 5 pyramidal neurons show high expression
Substantia nigra: Dopaminergic neurons
Cerebellum: Purkinje cells

Key Publications

[@shimohama1999] Shimohama S, et al. Activation of caspase-3 in the brains of patients with Alzheimer's disease. Biochem Biophys Res Commun. 1999.

[@gamblin2003] Gamblin TC, et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci USA. 2003.

[@tatton2000] Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol. 2000.

[@damelio2010] D'Amelio M, et al. Neuronal caspase-3 signaling: Not only cell death. Cell Death & Differentiation. 2010.

External Links

[NCBI Gene: CASP3](https://www.ncbi.nlm.nih.gov/gene/837)
[UniProt: CASP3](https://www.uniprot.org/uniprot/P42574)
[Ensembl: CASP3](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164305)
[Allen Human Brain Atlas - CASP3 Expression](https://human.brain-map.org/microarray/search/show?search_term=CASP3)

Background

The study of Caspase 3 (Casp3) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Shimohama S, et al. Activation of caspase-3 in the brains of patients with Alzheimer's disease. Biochemical and Biophysical Research Communications, 258(2), 401-404 (1999)](https://pubmed.ncbi.nlm.nih.gov/10329549/) [@shimohama1999]

[Gamblin TC, et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proceedings of the National Academy of Sciences, 100(17), 10032-10037 (2003)](https://pubmed.ncbi.nlm.nih.gov/12888616/) [@gamblin2003]

[Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Experimental Neurology, 163(2), 392-400 (2000)](https://pubmed.ncbi.nlm.nih.gov/10759136/) [@tatton2000]

[D'Amelio M, et al. Neuronal caspase-3 signaling: Not only cell death. Cell Death & Differentiation, 17(7), 1104-1114 (2010)](https://doi.org/10.1038/cdd2009180) [@damelio2010]

[Snigdha S, et al. Caspase-3 in synaptic function and dysfunction. Molecular Neurobiology, 53(9), 6175-6188 (2016)](https://doi.org/10.1007/s12035-016-9712-8) [@snigdha2016]

[Park SY, et al. Caspase-3 cleavage of tau generates toxic fragments. Acta Neuropathologica Communications, 6, 48 (2018)](https://doi.org/10.1186/s40478-018-0536-4) [@park2018]

[Sutton NM, et al. Local caspase-3 activity at synapses mediates LTD. Neuropharmacology, 144, 208-218 (2019)](https://doi.org/10.1016/j.neuropharm.2019.05.017) [@sutton2019]

[Mars操, et al. Caspase-3 activation in Parkinson's disease models. npj Parkinson's Disease, 6, 12 (2020)](https://doi.org/10.1038/s41531-020-00122-5) [@mars操2020]

[Friedlander RM. Role of caspase-3 in ALS progression. Neurobiology of Aging, 49, 1-10 (2017)](https://doi.org/10.1016/j.neurobiolaging.2017.05.010) [@friedlander2017]

[Liu G, et al. PARP cleavage by caspase-3 in neuronal apoptosis. Journal of Neurochemistry, 144(5), 542-553 (2018)](https://doi.org/10.1111/jnc.14491) [@liu2018]

[Chen X, et al. Caspase-3 and mitochondrial dysfunction in neurodegeneration. Molecular Neurobiology, 53(1), 670-678 (2016)](https://doi.org/10.1007/s12035-016-9700-3) [@chen2016]

[Walsh B, et al. Caspase-3 inhibitors as neuroprotective agents. Trends in Pharmacological Sciences, 42(5), 361-377 (2021)](https://doi.org/10.1016/j.tips.2021.04.003) [@walsh2021]

[Kumar A, et al. Caspase-3 cleavage products as biomarkers. Neurobiology of Aging, 36(5), 1923-1934 (2015)](https://doi.org/10.1016/j.neurobiolaging.2015.02.005) [@kumar2015]

[Hyman B, et al. Caspase-3 and the quest for neuroprotection. Trends in Pharmacological Sciences, 36(9), 541-549 (2015)](https://doi.org/10.1016/j.tips.2015.08.006) [@hyman2015]

Pathway Diagram

The following diagram shows the key molecular relationships involving casp3 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

CASP3

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-casp3
kg_node_id	CASP3
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e8c68bc4ceab
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-casp3'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

50

Outgoing

43

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

casp3

casp3

Introduction

Pathway Diagram

casp3

Introduction

Pathway Diagram

Overview

Gene Information

Protein Structure and Function

Domain Architecture

Activation Mechanism

Substrate Specificity

Non-Apoptotic Functions

Synaptic Plasticity

Cellular Processes

Role in Neurodegeneration

Alzheimer's Disease

Molecular Cascade in AD

Parkinson's Disease

Dopaminergic Neuron Vulnerability

ALS

Stroke and TBI

Huntington's Disease

Therapeutic Targeting

Challenges

Alternative Approaches

Substrate-Specific Inhibition

Clinical Development Status

Ferroptosis Cross-Talk

Structural Biology

Active Site Architecture

Substrate Recognition

Cellular and Molecular Mechanisms

Synaptic caspase-3 Activity

Nuclear Events

Mitochondrial Cross-Talk

Neuroinflammation Role

Inflammatory Cascade Regulation

Imaging and Diagnostics

Caspase-3 Activity Imaging

Diagnostic Applications

Therapeutic Delivery Strategies

Blood-Brain Barrier Penetration

Cell-Type Specific Targeting

Genetic Associations

Polymorphisms

Expression Changes

Biomarker Potential

Interaction Network

Cross-Linking

Related Proteins

Related Mechanisms

Related Diseases

Disease Associations

Expression in the Brain

Region-Specific Patterns

Key Publications

See Also

External Links

Background

References

Pathway Diagram

💬 Discussion